Advertisement

Psoriasis Therapy in the Geriatric Population

  • Daniel C. ButlerEmail author
  • John Y. M. Koo

Abstract

The geriatric population of the USA is rapidly growing, and estimates indicate that it will comprise one-fourth of the total population by year 2025. These patients make up a significant percentage of those treated for psoriasis; however there is little literature focused on specific cutaneous concerns within the population. Physiologic changes associated with aging, concurrent comorbidities, and polypharmacy can all complicate a clinician’s treatment approach and lead to inadequate management or undertreatment. This chapter hopes to serve as a clinical aid in safely addressing a geriatric patient’s cutaneous needs.

Keywords

Geriatric Aging Psoriasis Biologics Polypharmacy Dermatogeriatrics Geriatric dermatology 

References

  1. 1.
    Bureau UC. Projected resident population of the United States as of July 1, 2025, middle series. Washington, DC: Population Division; 2002.Google Scholar
  2. 2.
    Bell LM, Sedlack R, Beard CM, Perry HO, Michet CJ, Kurland LT. Incidence of psoriasis in Rochester, Minn, 1980–1983. Arch Dermatol. 1991;127(8):1184–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Wong JW, Koo JY. The safety of systemic treatments that can be used for geriatric psoriasis patients: a review. Dermatol Res Pract. 2012;2012:367475.PubMedCentralPubMedGoogle Scholar
  4. 4.
    Mehta NN, Yu Y, Pinnelas R, et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med. 2011;124(8):775.e1–6.CrossRefGoogle Scholar
  5. 5.
    Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc. 2013;2(2), e000062.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Hugh J, Van Voorhees AS, Nijhawan RI, et al. From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies. J Am Acad Dermatol. 2014;70(1):168–77.PubMedCrossRefGoogle Scholar
  7. 7.
    van der Voort EA, Koehler EM, Dowlatshahi EA, et al. Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: Results from a population-based study. J Am Acad Dermatol. 2014;70(3):517–24.PubMedCrossRefGoogle Scholar
  8. 8.
    Coskey RJ. Adverse effects of corticosteroids: I. Topical and intralesional. Clin Dermatol. 1986;4(1):155–60.PubMedCrossRefGoogle Scholar
  9. 9.
    du Vivier A, Stoughton RB. Tachyphylaxis to the action of topically applied corticosteroids. Arch Dermatol. 1975;111(5):581–3.PubMedCrossRefGoogle Scholar
  10. 10.
    Singh G, Singh PK. Tachyphylaxis to topical steroid measured by histamine-induced wheal suppression. Int J Dermatol. 1986;25(5):324–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Grozdev IS, Van Voorhees AS, Gottlieb AB, et al. Psoriasis in the elderly: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2011;65(3):537–45.PubMedCrossRefGoogle Scholar
  12. 12.
    Parslew R, Traulsen J. Efficacy and local safety of a calcipotriol/betamethasone dipropionate ointment in elderly patients with psoriasis vulgaris. Eur J Dermatol. 2005;15(1):37–9.PubMedGoogle Scholar
  13. 13.
    Gould JW, Mercurio MG, Elmets CA. Cutaneous photosensitivity diseases induced by exogenous agents. J Am Acad Dermatol. 1995;33(4):551–73. quiz 574-556.PubMedCrossRefGoogle Scholar
  14. 14.
    Bressler R, Bahl JJ. Principles of drug therapy for the elderly patient. Mayo Clin Proc. 2003;78(12):1564–77.PubMedCrossRefGoogle Scholar
  15. 15.
    Turnheim K. Drug dosage in the elderly. Is it rational? Drugs Aging. 1998;13(5):357–79.PubMedCrossRefGoogle Scholar
  16. 16.
    Flammiger A, Maibach H. Drug dosage in the elderly: dermatological drugs. Drugs Aging. 2006;23(3):203–15.PubMedCrossRefGoogle Scholar
  17. 17.
    Boffa MJ. Methotrexate for psoriasis: current European practice. A postal survey. J Eur Acad Dermatol Venereol. 2005;19(2):196–202.PubMedCrossRefGoogle Scholar
  18. 18.
    Evans WE, Christensen ML. Drug interactions with methotrexate. J Rheumatol Suppl. 1985;12 Suppl 12:15–20.PubMedGoogle Scholar
  19. 19.
    Bhutani T, Koo J. A review of the chemopreventative effects of oral retinoids for internal neoplasms. J Drugs Dermatol. 2011;10(11):1292–8.PubMedGoogle Scholar
  20. 20.
    Falck P, Asberg A, Byberg KT, et al. Reduced elimination of cyclosporine A in elderly (>65 years) kidney transplant recipients. Transplantation. 2008;86(10):1379–83.PubMedCrossRefGoogle Scholar
  21. 21.
    Heydendael VM, Spuls PI, Ten Berge IJ, Opmeer BC, Bos JD, de Rie MA. Cyclosporin trough levels: is monitoring necessary during short-term treatment in psoriasis? A systematic review and clinical data on trough levels. Br J Dermatol. 2002;147(1):122–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Infliximab. (package Insert). Toronto, Canada 2010.Google Scholar
  23. 23.
    Ustekinumab. (package insert). Horsham, PA 2011.Google Scholar
  24. 24.
    Etanercept. (package insert). Thousand Oaks, CA 1998–2011.Google Scholar
  25. 25.
    Reich K, Langley RG, Lebwohl M, et al. Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol. 2011;164(4):862–72.PubMedCrossRefGoogle Scholar
  26. 26.
    Adalimumab. (package insert). North Chicago, Ill 2002.Google Scholar
  27. 27.
    Gottlieb AB, Boehncke WH, Darif M. Safety and efficacy of alefacept in elderly patients and other special populations. J Drugs Dermatol. 2005;4(6):718–24.PubMedGoogle Scholar
  28. 28.
    Militello G, Xia A, Stevens SR, Van Voorhees AS. Etanercept for the treatment of psoriasis in the elderly. J Am Acad Dermatol. 2006;55(3):517–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Menter A, Gordon KB, Leonardi CL, Gu Y, Goldblum OM. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol. 2010;63(3):448–56.PubMedCrossRefGoogle Scholar
  30. 30.
    Fleischmann R, Baumgartner SW, Weisman MH, Liu T, White B, Peloso P. Long term safety of etanercept in elderly subjects with rheumatic diseases. Ann Rheum Dis. 2006;65(3):379–84.PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Galloway JB, Hyrich KL, Mercer LK, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford). 2011;50(1):124–31.CrossRefGoogle Scholar
  32. 32.
    Piaserico S, Conti A, Lo Console F, et al. Efficacy and safety of systemic treatments for psoriasis in elderly patients. Acta Derm Venereol. 2014;94(3):293–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.Department of DermatologyMassachusetts General HospitalBostonUSA
  2. 2.Department of DermatologyUCSFSan FranciscoUSA

Personalised recommendations